Myovant Sciences Ltd. to Post FY2026 Earnings of $0.35 Per Share, SVB Leerink Forecasts (NYSE:MYOV)

Myovant Sciences Ltd. (NYSE:MYOVGet Rating) – Stock analysts at SVB Leerink decreased their FY2026 EPS estimates for shares of Myovant Sciences in a research report issued to clients and investors on Tuesday, August 2nd. SVB Leerink analyst R. Ruiz now expects that the company will post earnings per share of $0.35 for the year, down from their previous forecast of $0.40. SVB Leerink has a “Market Perform” rating and a $12.00 price objective on the stock. The consensus estimate for Myovant Sciences’ current full-year earnings is ($1.91) per share.

Myovant Sciences (NYSE:MYOVGet Rating) last announced its quarterly earnings results on Tuesday, May 10th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.08). The business had revenue of $57.57 million for the quarter, compared to analysts’ expectations of $60.76 million.

Several other analysts have also recently weighed in on MYOV. The Goldman Sachs Group raised their price objective on shares of Myovant Sciences from $9.00 to $10.00 and gave the company a “neutral” rating in a research report on Thursday, July 28th. Robert W. Baird lowered their price objective on shares of Myovant Sciences from $30.00 to $20.00 in a research report on Wednesday, April 13th.

Myovant Sciences Price Performance

Shares of NYSE:MYOV opened at $14.18 on Wednesday. The firm has a fifty day moving average price of $12.24 and a two-hundred day moving average price of $12.16. Myovant Sciences has a one year low of $7.67 and a one year high of $27.43. The company has a market cap of $1.36 billion, a price-to-earnings ratio of -8.06 and a beta of 2.40.

Insider Buying and Selling

In related news, General Counsel Matthew Lang sold 3,702 shares of Myovant Sciences stock in a transaction on Wednesday, July 6th. The shares were sold at an average price of $13.40, for a total value of $49,606.80. Following the transaction, the general counsel now owns 272,335 shares in the company, valued at approximately $3,649,289. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other Myovant Sciences news, insider Ferreira Juan Camilo Arjona sold 2,755 shares of the business’s stock in a transaction dated Wednesday, July 6th. The shares were sold at an average price of $13.40, for a total value of $36,917.00. Following the transaction, the insider now owns 255,992 shares in the company, valued at $3,430,292.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, General Counsel Matthew Lang sold 3,702 shares of the business’s stock in a transaction dated Wednesday, July 6th. The shares were sold at an average price of $13.40, for a total transaction of $49,606.80. Following the completion of the transaction, the general counsel now owns 272,335 shares in the company, valued at approximately $3,649,289. The disclosure for this sale can be found here. Insiders have sold a total of 10,096 shares of company stock worth $133,358 in the last 90 days. 1.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On Myovant Sciences

Large investors have recently modified their holdings of the stock. Bellevue Group AG boosted its stake in Myovant Sciences by 6.9% during the fourth quarter. Bellevue Group AG now owns 6,169,039 shares of the company’s stock worth $96,052,000 after acquiring an additional 400,000 shares in the last quarter. State Street Corp boosted its stake in Myovant Sciences by 16.2% during the first quarter. State Street Corp now owns 3,334,935 shares of the company’s stock worth $44,421,000 after acquiring an additional 464,627 shares in the last quarter. BlackRock Inc. boosted its stake in Myovant Sciences by 3.5% during the first quarter. BlackRock Inc. now owns 1,202,975 shares of the company’s stock worth $16,023,000 after acquiring an additional 41,087 shares in the last quarter. Pier Capital LLC boosted its stake in Myovant Sciences by 1.1% during the fourth quarter. Pier Capital LLC now owns 296,166 shares of the company’s stock worth $4,611,000 after acquiring an additional 3,190 shares in the last quarter. Finally, Rafferty Asset Management LLC boosted its stake in Myovant Sciences by 121.7% during the fourth quarter. Rafferty Asset Management LLC now owns 252,190 shares of the company’s stock worth $3,927,000 after acquiring an additional 138,428 shares in the last quarter. Institutional investors own 32.55% of the company’s stock.

About Myovant Sciences

(Get Rating)

Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.

Featured Articles

Earnings History and Estimates for Myovant Sciences (NYSE:MYOV)

Want More Great Investing Ideas?

Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.